These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 27456948)

  • 1. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
    Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
    Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
    Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
    Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Aug; 144(2):278-88. PubMed ID: 26185313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
    Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
    Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
    Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
    Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO
    Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
    Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
    Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
    Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.
    Inoue H; Horii R; Ito Y; Iwase T; Ohno S; Akiyama F
    Breast Cancer; 2018 May; 25(3):268-274. PubMed ID: 29185202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer.
    Lee HJ; Park IA; Song IH; Shin SJ; Kim JY; Yu JH; Gong G
    J Clin Pathol; 2016 May; 69(5):422-30. PubMed ID: 26475777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
    Ogiya R; Niikura N; Kumaki N; Bianchini G; Kitano S; Iwamoto T; Hayashi N; Yokoyama K; Oshitanai R; Terao M; Morioka T; Tsuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Cancer Sci; 2016 Dec; 107(12):1730-1735. PubMed ID: 27727484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
    Ahn SG; Cha YJ; Bae SJ; Yoon C; Lee HW; Jeong J
    BMC Cancer; 2018 Mar; 18(1):320. PubMed ID: 29573739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes.
    Kim A; Heo SH; Kim YA; Gong G; Jin Lee H
    Am J Clin Pathol; 2016 Jul; 146(1):137-44. PubMed ID: 27402610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
    Kim A; Lee SJ; Kim YK; Park WY; Park DY; Kim JY; Lee CH; Gong G; Huh GY; Choi KU
    Sci Rep; 2017 Sep; 7(1):11671. PubMed ID: 28916815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Chung YR; Kim HJ; Jang MH; Park SY
    Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
    Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
    Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
    Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
    Sci Rep; 2019 Feb; 9(1):1583. PubMed ID: 30733496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.